Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story
出版年份 2023 全文链接
标题
Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story
作者
关键词
-
出版物
ANNALS OF THE RHEUMATIC DISEASES
Volume -, Issue -, Pages ard-2023-223850
出版商
BMJ
发表日期
2023-11-04
DOI
10.1136/ard-2023-223850
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)
- (2023) Michelle Petri et al. LANCET
- Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis
- (2023) Gerd R Burmester et al. RMD Open
- Filgotinib for the Treatment of Small Bowel Crohn’s Disease: The DIVERGENCE 1 Trial
- (2023) Geert R. D’Haens et al. Gastroenterology
- Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study
- (2022) Farzin Khosrow-Khavar et al. ANNALS OF THE RHEUMATIC DISEASES
- The pan‐JAK inhibitor delgocitinib in a cream formulation demonstrates dose‐response in chronic hand eczema in a 16‐week randomised phase 2b trial
- (2022) Margritta Worm et al. BRITISH JOURNAL OF DERMATOLOGY
- Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis
- (2022) Steven R. Ytterberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial
- (2022) E Wesley Ely et al. Lancet Respiratory Medicine
- MANTA and MANTA-RAy: Rationale and Design of Trials Evaluating Effects of Filgotinib on Semen Parameters in Patients with Inflammatory Diseases
- (2022) Wayne J. G. Hellstrom et al. ADVANCES IN THERAPY
- Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis
- (2022) Philip J Mease et al. ANNALS OF THE RHEUMATIC DISEASES
- Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials
- (2022) Silvio Danese et al. LANCET
- Two Phase 3 Trials of Baricitinib for Alopecia Areata
- (2022) Brett King et al. NEW ENGLAND JOURNAL OF MEDICINE
- Structure of a Janus kinase cytokine receptor complex reveals the basis for dimeric activation
- (2022) Caleb R. Glassman et al. SCIENCE
- The pan-JAK inhibitor LAS194046 reduces neutrophil activation from severe asthma and COPD patients in vitro
- (2022) Javier Milara et al. Scientific Reports
- Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial
- (2022) Cameron R Wolfe et al. Lancet Respiratory Medicine
- Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial
- (2022) Désirée van der Heijde et al. ANNALS OF THE RHEUMATIC DISEASES
- Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial
- (2022) April W. Armstrong et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance
- (2022) Christina Charles-Schoeman et al. ANNALS OF THE RHEUMATIC DISEASES
- The JAK-STAT pathway at 30: Much learned, much more to do
- (2022) Rachael L. Philips et al. CELL
- Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 POETYK PSO-2 trial
- (2022) Bruce Strober et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo
- (2022) David Rosmarin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Characterization of Selective and Potent JAK1 Inhibitors Intended for the Inhaled Treatment of Asthma
- (2022) Magnus Nilsson et al. Drug Design Development and Therapy
- Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis
- (2022) Andreas Kerschbaumer et al. ANNALS OF THE RHEUMATIC DISEASES
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
- (2022) Josef S Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis
- (2022) Alexandre Sepriano et al. ANNALS OF THE RHEUMATIC DISEASES
- STAT6 gain-of-function variant exacerbates multiple allergic symptoms
- (2022) Ichiro Takeuchi et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II , Randomized, Double‐Blind , Placebo‐Controlled Trial
- (2022) Eric Morand et al. Arthritis & Rheumatology
- Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial
- (2021) René Westhovens et al. ANNALS OF THE RHEUMATIC DISEASES
- Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial
- (2021) Bernard Combe et al. ANNALS OF THE RHEUMATIC DISEASES
- Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy Phase 3 trial in the United States and Canada (BREEZE-AD5)
- (2021) Eric L. Simpson et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study
- (2021) Atul Deodhar et al. ANNALS OF THE RHEUMATIC DISEASES
- Inhaled JAK inhibitor GDC-0214 reduces exhaled nitric oxide in patients with mild asthma: A randomized, controlled, proof-of-activity trial
- (2021) Irene E. Braithwaite et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Efficacy and Safety of Ruxolitinib Cream for the Treatment of Atopic Dermatitis: Results From Two Phase 3, Randomized, Double-Blind Studies
- (2021) Kim Papp et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
- (2021) Brett King et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis
- (2021) Thomas Bieber et al. NEW ENGLAND JOURNAL OF MEDICINE
- POS1170 SELF-PROTECTION STRATEGIES, HEALTH BEHAVIOR AND DISEASE ACTIVITY DURING THE FIRST WAVE, RE-OPENING AND SECOND WAVE OF THE COVID-19 PANDEMIC IN >7000 DANISH PATIENTS WITH INFLAMMATORY ARTHRITIS
- (2021) B. Glintborg et al. ANNALS OF THE RHEUMATIC DISEASES
- AB0222 COMPARISON OF SELF-INJECTION DEVICES FOR ADMINISTERING ANTI-TUMOR NECROSIS FACTOR AGENTS USING THE ORIGINAL QUESTIONNAIRE IN PATIENTS WITH RHEUMATOID ARTHRITIS
- (2021) Y. Hirano et al. ANNALS OF THE RHEUMATIC DISEASES
- Janus kinase (JAK)-inhibitors and coronavirus disease 2019 (Covid-19) outcomes: a systematic review and meta-analysis
- (2021) Ronal Yosua Limen et al. Expert Review of Anti-Infective Therapy
- Tyrosine kinase 2 and Janus kinase‒signal transducer and activator of transcription signaling and inhibition in plaque psoriasis
- (2021) James G. Krueger et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial
- (2021) Kristian Reich et al. LANCET
- Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials
- (2021) Emma Guttman-Yassky et al. LANCET
- Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial
- (2021) Brian G Feagan et al. LANCET
- Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease
- (2021) Robert Zeiser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia
- (2021) Patrícia O. Guimarães et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus
- (2021) Sarfaraz A. Hasni et al. Nature Communications
- Upadacitinib in Active Ankylosing Spondylitis: 1‐Year Results From the Double‐Blind, Placebo‐Controlled SELECT‐AXIS 1 Study and Open‐Label Extension
- (2021) Atul Deodhar et al. Arthritis & Rheumatology
- Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial
- (2021) Vincent C Marconi et al. Lancet Respiratory Medicine
- Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials
- (2020) E.L. Simpson et al. BRITISH JOURNAL OF DERMATOLOGY
- An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data
- (2020) Gerd R. Burmester et al. DRUG SAFETY
- Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis
- (2020) William J. Sandborn et al. GASTROENTEROLOGY
- Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn’s Disease
- (2020) William J. Sandborn et al. GASTROENTEROLOGY
- Homozygous STAT2 gain-of-function mutation by loss of USP18 activity in a patient with type I interferonopathy
- (2020) Conor Gruber et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study
- (2020) Hidemi Nakagawa et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- JAK Inhibitor Therapy in a Child with Inherited USP18 Deficiency
- (2020) Fahad Alsohime et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ruxolitinib treatment of a patient with steroid-dependent severe autoimmunity due to STAT1 gain-of-function mutation
- (2020) Kunihiko Moriya et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial
- (2020) Yang Cao et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19
- (2020) Tobias Herold et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-blind, Placebo-controlled Trial
- (2020) Seth B. Forman et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study
- (2020) Hideto Kameda et al. RHEUMATOLOGY
- Fenebrutinib versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double-Blind, Phase II Trial (ANDES Study)
- (2020) Stanley Cohen et al. Arthritis & Rheumatology
- Efficacy and Safety of PF‐06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor in Patients with Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate
- (2020) Michael F. Robinson et al. Arthritis & Rheumatology
- Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data
- (2020) Philip Mease et al. ANNALS OF THE RHEUMATIC DISEASES
- Safety of New Biologics (Vedolizumab and Ustekinumab) and Small Molecules (Tofacitinib) During Pregnancy: A Review
- (2020) Javier P. Gisbert et al. DRUGS
- Small Molecule NF-κB Pathway Inhibitors in Clinic
- (2020) Venkataramanan Ramadass et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study
- (2020) Fabrizio Cantini et al. JOURNAL OF INFECTION
- Discovery of a Janus Kinase Inhibitor Bearing a Highly Three-Dimensional Spiro Scaffold: JTE-052 (Delgocitinib) as a New Dermatological Agent to Treat Inflammatory Skin Disorders
- (2020) Satoru Noji et al. JOURNAL OF MEDICINAL CHEMISTRY
- Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
- (2020) Eric L Simpson et al. LANCET
- Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial
- (2020) David Rosmarin et al. LANCET
- Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis
- (2020) Jonathan I. Silverberg et al. JAMA Dermatology
- “Small” Intestinal Immunopathology Plays a “Big” Role in Lethal Cytokine Release Syndrome, and Its Modulation by Interferon-γ, IL-17A, and a Janus Kinase Inhibitor
- (2020) Shiv D. Kale et al. Frontiers in Immunology
- Age-based (
- (2020) Kevin L Winthrop et al. ANNALS OF THE RHEUMATIC DISEASES
- A pooled safety analysis of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis treated over a median of 2 years
- (2020) Tsutomu Takeuchi et al. Modern Rheumatology
- STAT1 Gain of Function, Type 1 Diabetes, and Reversal with JAK Inhibition
- (2020) Natalia S. Chaimowitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
- (2020) John H. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inborn errors of type I IFN immunity in patients with life-threatening COVID-19
- (2020) Qian Zhang et al. SCIENCE
- Early-onset autoimmunity associated with SOCS1 haploinsufficiency
- (2020) Jérôme Hadjadj et al. Nature Communications
- Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis
- (2020) Kristian Reich et al. JAMA Dermatology
- Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia
- (2020) Olivier Hermine et al. JAMA Internal Medicine
- Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia
- (2020) Carlo Salvarani et al. JAMA Internal Medicine
- Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2
- (2020) Philip J Mease et al. ANNALS OF THE RHEUMATIC DISEASES
- Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques
- (2020) Timothy N. Hoang et al. CELL
- Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
- (2020) Andre C. Kalil et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia
- (2020) Carlos Salama et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mycobacterium Intracellulare Infection Associated with TYK2 Deficiency: A Case Report and Review of the Literature
- (2020) Wanru Guo et al. Infection and Drug Resistance
- Cardiovascular Safety During Treatment with Baricitinib in Rheumatoid Arthritis
- (2019) Peter C. Taylor et al. Arthritis & Rheumatology
- The γc Family of Cytokines: Basic Biology to Therapeutic Ramifications
- (2019) Warren J. Leonard et al. IMMUNITY
- Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study
- (2019) Josef S Smolen et al. LANCET
- T cell pathology in skin inflammation
- (2019) Robert Sabat et al. Seminars in Immunopathology
- Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long‐Term Extension Studies of Tofacitinib in Patients with Rheumatoid Arthritis
- (2019) Christina Charles‐Schoeman et al. Arthritis & Rheumatology
- Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3)
- (2019) Yoshiya Tanaka et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan
- (2019) Tsutomu Takeuchi et al. ANNALS OF THE RHEUMATIC DISEASES
- Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy
- (2019) Mark C. Genovese et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Upadacitinib versus Placebo or Adalimumab in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase 3, Double‐Blind, Randomized Controlled Trial
- (2019) Roy Fleischmann et al. Arthritis & Rheumatology
- 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases
- (2019) Victoria Furer et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of topical delgocitinib in patients with chronic hand eczema: data from a randomised, double‐blind, vehicle‐controlled Phase 2a study
- (2019) M. Worm et al. BRITISH JOURNAL OF DERMATOLOGY
- Preferential Inhibition of JAK1 Relative to JAK3 by Upadacitinib: Exposure‐Response Analyses of Ex Vivo Data From 2 Phase 1 Clinical Trials and Comparison to Tofacitinib
- (2019) Mohamed‐Eslam F. Mohamed et al. JOURNAL OF CLINICAL PHARMACOLOGY
- The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors
- (2019) Katie Bechman et al. PHARMACOLOGICAL RESEARCH
- Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial
- (2019) Jon T. Giles et al. Arthritis & Rheumatology
- Upadacitinib: First Approval
- (2019) Sean Duggan et al. DRUGS
- Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream
- (2019) Brian S. Kim et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Upadacitinib in Adults With Moderate-to-Severe Atopic Dermatitis: 16-Week Results From a Randomized, Placebo-Controlled Trial
- (2019) Emma Guttman-Yassky et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Long‐term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis
- (2019) Hidemi Nakagawa et al. JOURNAL OF DERMATOLOGY
- Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial
- (2019) Désirée van der Heijde et al. LANCET
- Emerging Topical and Systemic JAK Inhibitors in Dermatology
- (2019) Farzan Solimani et al. Frontiers in Immunology
- Tofacitinib in patients with moderate to severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study
- (2018) F. Valenzuela et al. BRITISH JOURNAL OF DERMATOLOGY
- Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre, randomized, vehicle-controlled clinical study
- (2018) H. Nakagawa et al. BRITISH JOURNAL OF DERMATOLOGY
- Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib
- (2018) Kevin L Winthrop et al. INFLAMMATORY BOWEL DISEASES
- Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis
- (2018) Uma Mahadevan et al. INFLAMMATORY BOWEL DISEASES
- Utility of Ruxolitinib in a Child with Chronic Mucocutaneous Candidiasis Caused by a Novel STAT1 Gain-of-Function Mutation
- (2018) Markéta Bloomfield et al. JOURNAL OF CLINICAL IMMUNOLOGY
- JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies
- (2018) Gina A. Montealegre Sanchez et al. JOURNAL OF CLINICAL INVESTIGATION
- OP033 The effect of tofacitinib on serum lipids and cardiovascular safety in patients with ulcerative colitis: results from the tofacitinib ulcerative colitis clinical programme
- (2018) B E Sands et al. Journal of Crohns & Colitis
- Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study
- (2018) Bruce E Sands et al. Journal of Crohns & Colitis
- Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial
- (2018) Mark C Genovese et al. LANCET
- Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial
- (2018) Gerd R Burmester et al. LANCET
- Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial
- (2018) Daniel J Wallace et al. LANCET
- Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study
- (2018) Désirée van der Heijde et al. CLINICAL RHEUMATOLOGY
- Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment
- (2018) Josef S. Smolen et al. JOURNAL OF RHEUMATOLOGY
- Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials
- (2018) William J. Sandborn et al. Clinical Gastroenterology and Hepatology
- Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial
- (2018) Désirée van der Heijde et al. LANCET
- Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial
- (2018) Philip Mease et al. LANCET
- Clinical significance of Janus Kinase inhibitor selectivity
- (2018) Ernest H Choy RHEUMATOLOGY
- Comparative risk of venous thromboembolism with tofacitinib versus tumor necrosis factor inhibitors: A cohort study of rheumatoid arthritis patients
- (2018) Rishi J. Desai et al. Arthritis & Rheumatology
- A novel JAK inhibitor JTE-052 reduces skin inflammation and ameliorates chronic dermatitis in rodent models: Comparison with conventional therapeutic agents
- (2017) Atsuo Tanimoto et al. EXPERIMENTAL DERMATOLOGY
- Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
- (2017) Julian Panés et al. GUT
- JAK1 gain-of-function causes an autosomal dominant immune dysregulatory and hypereosinophilic syndrome
- (2017) Kate L. Del Bel et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: A Phase 3, randomized, double-blind, placebo-controlled study
- (2017) JianZhong Zhang et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- Paracoccidioidomycosis Associated With a Heterozygous STAT4 Mutation and Impaired IFN-γ Immunity
- (2017) Lena F Schimke et al. JOURNAL OF INFECTIOUS DISEASES
- Herpes zoster in psoriasis patients treated with tofacitinib
- (2017) Kevin L. Winthrop et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata
- (2017) Cheryl B. Bayart et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial
- (2017) Séverine Vermeire et al. LANCET
- Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial
- (2017) Roy Fleischmann et al. LANCET
- Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: Subgroup analyses of four multinational phase 3 randomized trials
- (2017) Yoshiya Tanaka et al. Modern Rheumatology
- Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
- (2017) NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis
- (2017) Philip Mease et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors
- (2017) Dafna Gladman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
- (2017) Peter C. Taylor et al. NEW ENGLAND JOURNAL OF MEDICINE
- ISG15: In Sickness and in Health
- (2017) Mark Hermann et al. TRENDS IN IMMUNOLOGY
- Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate
- (2017) A. J. Kivitz et al. Arthritis & Rheumatology
- Genome-Wide Association Meta-Analysis Reveals Novel Juvenile Idiopathic Arthritis Susceptibility Loci
- (2017) Laura A. McIntosh et al. Arthritis & Rheumatology
- Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis
- (2017) Mark C. Genovese et al. Arthritis & Rheumatology
- Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment
- (2017) Roy Fleischmann et al. Arthritis & Rheumatology
- An Activating Janus Kinase-3 Mutation Is Associated with Cytotoxic T Lymphocyte Antigen-4-Dependent Immune Dysregulation Syndrome
- (2017) Heiko Sic et al. Frontiers in Immunology
- Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON)
- (2016) Josef S Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy of VX-509 (decernotinib) in combination with a disease-modifying antirheumatic drug in patients with rheumatoid arthritis: clinical and MRI findings
- (2016) Mark C Genovese et al. ANNALS OF THE RHEUMATIC DISEASES
- Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
- (2016) Maxime Dougados et al. ANNALS OF THE RHEUMATIC DISEASES
- The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis
- (2016) Bethany T. Samuelson et al. BLOOD COAGULATION & FIBRINOLYSIS
- Safety, pharmacokinetics and pharmacodynamics of GLPG0974, a potent and selective FFA2 antagonist, in healthy male subjects
- (2016) Florence Namour et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis
- (2016) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial
- (2016) R. Bissonnette et al. BRITISH JOURNAL OF DERMATOLOGY
- Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis
- (2016) Megan E. B. Clowse et al. DRUG SAFETY
- Next generation of small molecules in inflammatory bowel disease
- (2016) Pablo Olivera et al. GUT
- JAK inhibitor JTE-052 regulates contact hypersensitivity by downmodulating T cell activation and differentiation
- (2016) Wataru Amano et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study
- (2016) Y. Tanaka et al. JOURNAL OF RHEUMATOLOGY
- Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis
- (2016) Jashin J. Wu et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Baricitinib in Patients with Refractory Rheumatoid Arthritis
- (2016) Mark C. Genovese et al. NEW ENGLAND JOURNAL OF MEDICINE
- Network pharmacology of JAK inhibitors
- (2016) Devapregasan Moodley et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies
- (2016) Hendrik Schulze-Koops et al. RHEUMATOLOGY
- Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor
- (2016) Christina Charles-Schoeman et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist
- (2016) Christina Charles-Schoeman et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- JAK1 Takes a FERM Hold of Type II Cytokine Receptors
- (2016) Jeffrey J. Babon et al. STRUCTURE
- Biallelic JAK1 mutations in immunodeficient patient with mycobacterial infection
- (2016) Davide Eletto et al. Nature Communications
- ISG15 deficiency and increased viral resistance in humans but not mice
- (2016) Scott D. Speer et al. Nature Communications
- Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
- (2016) Mark C. Genovese et al. Arthritis & Rheumatology
- A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy
- (2016) Joel M. Kremer et al. Arthritis & Rheumatology
- JAK3 as an Emerging Target for Topical Treatment of Inflammatory Skin Diseases
- (2016) Ana Karina Alves de Medeiros et al. PLoS One
- Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study
- (2015) Tsutomu Takeuchi et al. ANNALS OF THE RHEUMATIC DISEASES
- Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme
- (2015) Jeffrey R Curtis et al. ANNALS OF THE RHEUMATIC DISEASES
- The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
- (2015) John J. O'Shea et al. Annual Review of Medicine
- A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis
- (2015) K. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Downmodulation of key inflammatory cell markers with a topical Janus kinase 1/2 inhibitor
- (2015) N. Punwani et al. BRITISH JOURNAL OF DERMATOLOGY
- Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials
- (2015) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Human TYK2 deficiency: Mycobacterial and viral infections without hyper-IgE syndrome
- (2015) Alexandra Y. Kreins et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial
- (2015) Hervé Bachelez et al. LANCET
- TYK2 Protein-Coding Variants Protect against Rheumatoid Arthritis and Autoimmunity, with No Evidence of Major Pleiotropic Effects on Non-Autoimmune Complex Traits
- (2015) Dorothée Diogo et al. PLoS One
- Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials
- (2015) Vibeke Strand et al. ARTHRITIS RESEARCH & THERAPY
- Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial
- (2015) Joel M Kremer et al. ARTHRITIS RESEARCH & THERAPY
- A Randomized, Double-Blind, Placebo-Controlled, Twelve-Week, Dose-Ranging Study of Decernotinib, an Oral Selective JAK-3 Inhibitor, as Monotherapy in Patients With Active Rheumatoid Arthritis
- (2015) Roy M. Fleischmann et al. Arthritis & Rheumatology
- VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis
- (2015) Mark C. Genovese et al. Arthritis & Rheumatology
- Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate
- (2014) Edward C Keystone et al. ANNALS OF THE RHEUMATIC DISEASES
- A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s Disease
- (2014) William J. Sandborn et al. Clinical Gastroenterology and Hepatology
- Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo
- (2014) Atsuo Tanimoto et al. INFLAMMATION RESEARCH
- Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases
- (2014) James D. Clark et al. JOURNAL OF MEDICINAL CHEMISTRY
- Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies
- (2014) J. Wollenhaupt et al. JOURNAL OF RHEUMATOLOGY
- A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of 2 Dosing Regimens of Fostamatinib in Patients with Rheumatoid Arthritis with an Inadequate Response to a Tumor Necrosis Factor- Antagonist
- (2014) M. C. Genovese et al. JOURNAL OF RHEUMATOLOGY
- Tofacitinib versus Methotrexate in Rheumatoid Arthritis
- (2014) Eun Bong Lee et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Significance of Asthma Clusters by Longitudinal Analysis in Korean Asthma Cohort
- (2014) So Young Park et al. PLoS One
- Critical Role of Jak2 in the Maintenance and Function of Adult Hematopoietic Stem Cells
- (2014) Hajime Akada et al. STEM CELLS
- Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials
- (2014) John D Isaacs et al. ARTHRITIS RESEARCH & THERAPY
- Rheumatoid arthritis increases the risk of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study
- (2013) Wei-Sheng Chung et al. ANNALS OF THE RHEUMATIC DISEASES
- Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study
- (2013) Iain B McInnes et al. ANNALS OF THE RHEUMATIC DISEASES
- Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study*
- (2013) Iain B McInnes et al. ANNALS OF THE RHEUMATIC DISEASES
- A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis
- (2013) W.C. Ports et al. BRITISH JOURNAL OF DERMATOLOGY
- The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis
- (2013) Srdan Verstovsek et al. BRITISH JOURNAL OF HAEMATOLOGY
- Dominant gain-of-function STAT1 mutations in FOXP3 wild-type immune dysregulation–polyendocrinopathy–enteropathy–X-linked–like syndrome
- (2013) Gulbu Uzel et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Two Rare Disease-Associated Tyk2 Variants Are Catalytically Impaired but Signaling Competent
- (2013) Z. Li et al. JOURNAL OF IMMUNOLOGY
- Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases
- (2013) L. Van Rompaey et al. JOURNAL OF IMMUNOLOGY
- Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
- (2013) Gerd R Burmester et al. LANCET
- JAKs and STATs in Immunity, Immunodeficiency, and Cancer
- (2013) John J. O'Shea et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Analysis of Genome-wide Association Studies for Crohn Disease and Psoriasis Identifies Seven Shared Susceptibility Loci
- (2012) David Ellinghaus et al. AMERICAN JOURNAL OF HUMAN GENETICS
- Randomized Phase 2b Trial of Tofacitinib (CP-690,550) in De Novo Kidney Transplant Patients: Efficacy, Renal Function and Safety at 1 Year
- (2012) F. Vincenti et al. AMERICAN JOURNAL OF TRANSPLANTATION
- The risk of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: a UK population-based outpatient cohort study
- (2012) Hyon K Choi et al. ANNALS OF THE RHEUMATIC DISEASES
- Forget personalised medicine and focus on abating disease activity
- (2012) Josef S Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study
- (2012) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- STATs Shape the Active Enhancer Landscape of T Cell Populations
- (2012) Golnaz Vahedi et al. CELL
- TYK2 rs34536443 polymorphism is associated with a decreased susceptibility to endometriosis-related infertility
- (2012) Carla Peluso et al. HUMAN IMMUNOLOGY
- Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis
- (2012) Naresh Punwani et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- The pathogenesis of rheumatoid arthritis: new insights from old clinical data?
- (2012) Josef S. Smolen et al. Nature Reviews Rheumatology
- SomaticSTAT3Mutations in Large Granular Lymphocytic Leukemia
- (2012) Hanna L.M. Koskela et al. NEW ENGLAND JOURNAL OF MEDICINE
- Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
- (2012) Roy Fleischmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)
- (2011) Kamran Ghoreschi et al. JOURNAL OF IMMUNOLOGY
- A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy of Oral SCIO-469, a p38 Mitogen-activated Protein Kinase Inhibitor, in Patients with Active Rheumatoid Arthritis
- (2011) MARK C. GENOVESE et al. JOURNAL OF RHEUMATOLOGY
- Selective functional inhibition of JAK-3 is sufficient for efficacy in collagen-induced arthritis in mice
- (2010) Tsung H. Lin et al. ARTHRITIS AND RHEUMATISM
- Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes
- (2010) Richard J. Riese et al. BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY
- Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050
- (2010) J. S. Fridman et al. JOURNAL OF IMMUNOLOGY
- Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis
- (2010) Debra M Meyer et al. Journal of Inflammation-London
- Meta-analysis of TYK2 gene polymorphisms association with susceptibility to autoimmune and inflammatory diseases
- (2010) Jin-Hui Tao et al. MOLECULAR BIOLOGY REPORTS
- The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo
- (2009) Joel M. Kremer et al. ARTHRITIS AND RHEUMATISM
- Janus kinases in immune cell signaling
- (2009) Kamran Ghoreschi et al. IMMUNOLOGICAL REVIEWS
- Inteferons pen the JAK–STAT pathway
- (2008) Christian Schindler et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis
- (2008) Anthony J Milici et al. ARTHRITIS RESEARCH & THERAPY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation